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nDOBJECTIVES The Registry of the Utilization of the TAo-TAVR approach using the Edwards SAPIEN Valve (ROUTE) was
established to assess the effectiveness and safety of the use of transaortic (TAo) access for transcatheter aortic valve
replacement (TAVR) procedures (NCT01991431).
BACKGROUND TAVR represents an alternative to surgical valve replacement in high-risk patients. Whereas the
transfemoral access route is used commonly as the first-line approach, transapical access is an option for patients not
suitable for transfemoral treatment mainly due to anatomic conditions. TAo-TAVR has been shown to be a viable
alternative surgical access route; however, only limited data on its effectiveness and safety has been published.
METHODS ROUTE is a multicenter, international, prospective, observational registry; data were collected from 18
centers across Europe starting in February 2013. Patients having severe calcific aortic stenosis were documented if they
were scheduled to undergo TAo-TAVR using an Edwards SAPIEN XT or a SAPIEN 3 valve. The primary endpoint was
30-day mortality. Secondary endpoints were intraprocedural or in hospital and 30-day complication rates.
RESULTS A total of 301 patients with a mean age of 81.7  5.9 years and an Society of Thoracic Surgeons score of 9.0 
7.6% were included. Valve success was documented in 96.7%. The 30-day mortality was 6.1% (18/293) (procedure-
related mortality: 3.1%; 9 of 293). The Valve Academic Research Consortium-2 defined complications included
myocardial infarction (1.0%), stroke (1.0%), transient ischemic attack (0.3%), major vascular complications (3.4%),
life-threatening bleeding (3.4%), and acute kidney injury (9.5%). In 3.3% of patients, paravalvular regurgitation was
classified as moderate or severe (10 of 300). Twenty-six patients (8.8%) required permanent pacemaker implantation.
CONCLUSIONS TAo access for TAVR seems to be a safe alternative to the transapical procedure.
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ABBR EV I A T I ON S
AND ACRONYMS
TA = transapical
TAo = transaortic access
TAVR = transcatheter aortic
valve replacement
TF = transfemoral
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1816I n patients with severe aortic stenosis,unsuitable for open heart surgery, trans-catheter aortic valve replacement
(TAVR) represents an alternative treatment
option (1). Transaortic access (TAo) is an
additional access route to transfemoral (TF)
or transapical (TA) routes. It is used in pa-
tients that are neither suitable for TF access,due to anatomic abnormalities or peripheral vascular
disease, nor TA access, due to respiratory disease or
decreased left ventricular function (2–7). Initial
studies investigating TAo-TAVR have reported ease
of access, good visualization, and low risk of hemor-
rhage, in addition to comparable complication and
mortality rates to the other access routes (4,7–9).
However, each of the approaches is associated with
advantages and disadvantages resulting in different
TAVR-related complications (10–14). Because the
majority of studies regarding TAo-TAVR using the
SAPIEN transcatheter heart valve have been single-
center case series and have included relatively low
numbers of patients, there is a need to confirm
morbidity and mortality outcomes by evaluating a
large, multinational population (3,6,9,15).SEE PAGE 1823With the aim of meeting this need, the ROUTE
(Registry of the Utilization of the TAo-TAVR approach
using the Edwards SAPIEN Valve) was established
(16). This is a multicenter, international, prospective
registry that included patients who received either
the SAPIEN XT or the SAPIEN 3 valves (Edwards
Lifesciences, Irvine, California) via TAo. The primary
aim of the study was to assess overall mortality dur-
ing a 30-day follow-up. Further, procedural charac-
teristics, complications, and TAVR-related mortality
were investigated.
METHODS
STUDY DESIGN AND SITE SELECTION. ROUTE is a
multicenter, multinational, prospective, observa-
tional registry (NCT01991431) (16). Patients were
enrolled consecutively at 18 centers across Europent of Cardiac Surgery, University of Padova, Italy; qDepartment of
ermany; rInstitute for Pharmacology and Preventive Medicine, Clo
fessional Education, Nyon, Switzerland; and the tInstitut Hospital
, Bonaros, Chocron, Cocchieri, Eichinger, Frank, Gerosa, Jagielak
nd Romano have received research funding and/or speaker hon
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by Edwards Lifesciences. Drs. Bapat and Frank contributed equa
t received March 24, 2016; revised manuscript received June 8, 2(France, Italy, Netherlands, the United Kingdom,
Poland, Finland, Denmark, Norway, Germany, and
Austria) from February 2013 through February 2015.
Each site was required to have prior experience with
TAo-TAVR using the SAPIEN valve (minimum 5 im-
plantations). All patients included in the registry pro-
vided written informed consent, and ethical approval
was obtained from the relevant committee at each site.
PATIENTS. Patients with severe calcific aortic steno-
sis were included if they were scheduled to undergo
TAo-TAVR using an Edwards SAPIEN XT or a SAPIEN
3 valve (16). Patients were excluded if they had
congenital unicuspid or bicuspid aortic valves; evi-
dence of intracardiac mass, thrombus, vegetation,
active infection, or endocarditis; an inability to
tolerate anticoagulation or antiplatelet agents; or
excessive calcification of the access site. Patients who
were scheduled to receive an additional procedure
besides TAVR, such as coronary artery bypass graft-
ing, were also excluded.
DOCUMENTATION AND ENDPOINTS. At admission, a
full cardiac history was taken, and comorbidities were
recorded. Further data were collected at the time of
the TAVR procedure, at discharge, and at 30 days
after the procedure. Complication rates were
defined according to the Valve Academic Research
Consortium-2 criteria (17). The information was
entered into an electronic database, at which point it
was checked for plausibility and completeness (16).
The primary endpoint was overall 30-day mortality.
Secondary endpoints were intraprocedural, in-
hospital, and 30-day complication rates.
STATISTICS. The required sample size was calculated
on the basis of an overall mortality of 7.1% at 30 days,
an estimate which relied on unpublished data from
the principal investigators (16). This gave an initial
required population of 200 patients. From February
2014, the newly approved SAPIEN 3 valve could also
be used. Therefore, in June 2014, the study was
expanded to include a further 100 patients.
Descriptive statistics are provided for all evaluable
data. Categorical variables are presented as absoluteCardiovascular Surgery, Robert-Bosch-Krankenhaus
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TABLE 1 Patient Characteristics
Age, yrs 81.7  5.9
Female 162/301 (53.8)
Current smoker 29/252 (9.6)
Left ventricular ejection fraction, % 52.5  12.2
Syncope/dizziness with exertion 105/301 (34.9)
Angina pectoris CCS class III or IV 40/281 (14.2)
Cardiac comorbidity
Coronary artery disease 184/301 (61.1)
Prior MI 46/299 (15.4)
Atrial fibrillation 94/299 (31.4)
Prior pacemaker implantation 23/301 (7.6)
Noncardiac comorbidity
Hypertension 231/299 (77.3)
Diabetes mellitus 79/299 (26.4)
Peripheral artery disease 128/301 (42.5)
Pulmonary disease 78/301 (25.9)
Pulmonary hypertension 95/297 (32.0)
Renal insufficiency or failure 95/301 (31.6)
Surgical risk
Logistic EuroScore II, % 8.8  9.6
STS score, % 9.0  7.6
Values are mean  SD or n/N (%).
CCS ¼ Canadian Cardiovascular Society; MI ¼ myocardial infarction; NYHA ¼
New York Heart Association; STS ¼ Society of Thoracic Surgeons.
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1817values and percentages. Continuous variables are
given as mean  SD. Change in aortic valve peak and
mean gradient between pre-procedure and post-pro-
cedure were compared using analysis of variance.
Centers and countrieswere included as random factors
in the model. The risk for overall 30-day mortality was
calculated using a logistic model, including age, left
ventricular ejection fraction, presence of syncope or
dizziness, prior pacemaker implantation, hyperten-
sion, peripheral artery disease, pulmonary hyperten-
sion, TF feasibility, and country as independent
possible risk factors.
RESULTS
PATIENTS. The 301 patients enrolled in ROUTE
(Figure 1) had a mean age of 81.7  5.9 years, with
53.8% being female (Table 1). The mean left ven-
tricular ejection fraction was 52.5  12.2%, a total
of 34.9% reported syncope or dizziness on exer-
tion, and 14.2% had angina pectoris class III or IV
(Canadian Cardiovascular Society). A high propor-
tion of patients (61.1%) had coronary artery disease,
15.4% had experienced a prior myocardial infarc-
tion, 31.4% experienced atrial fibrillation, and 7.6%
have previously had a pacemaker implanted. Arte-
rial hypertension was present in 77.3%, peripheral
artery disease in 42.5%, pulmonary hypertension in
32.0%, and renal insufficiency in 31.6%. The meanFIGURE 1 Patient Flow
FU ¼ follow-up.Logistic EuroScore II was 8.8  9.6%; Society of
Thoracic Surgeons score was 9.0  7.6%.
TAVR ACCESS. In 25.6% of patients, the TAo was
the only option due to contraindications for both,
the TA and TF approach, whereas 74.4% of patients
were deemed feasible to either the TA and/or TF
access (72.8% and 13.0%, respectively). In 48.0% of
patients (144 of 301), the TAo route was chosen
because of a center’s preference (Table 2), although
TA and/or TF access would have been feasible
as well (140 of 144; 97.2%). In 41% of patients,
peripheral artery disease or unsuitable vessels were
the reasons for using a TAo approach. The TAo
access via ministernotomy was chosen in the
majority of cases (96.0%).
PROCEDURAL CHARACTERISTICS. The mean dura-
tion of the TAVR procedure was 107.0  37.7 min,
with the mean fluoroscopy time being 12.4 
8.5 min (Table 3). The mean volume of contrast agent
used was 101.4  48.6 ml. Balloon aortic valvulo-
plasty before implantation was used in 74.0% of pa-
tients, with a post-dilation rate of 23.3%. Of the 301
performed procedures, the SAPIEN XT valve was
implanted in 58.1% of cases and the SAPIEN 3 in
41.9%. Three different valve sizes were used for the
TAVR procedures; the 23-mm diameter valve was
implanted in 27.7% of patients, the 26-mm diameter
in 48.3%, and the 29-mm diameter in 24.0%.
TABLE 2 Access Routes
Reasons for choosing transaortic route
Standard procedure at site 144/301 (48.0)
Peripheral artery disease 66/301 (22.0)
Vessel status 57/301 (19.0)
Significant respiratory disease 14/301 (4.7)
Poor left ventricular function 8/301 (2.7)
Multiple redo surgery 4/301 (1.3)
High risk for stroke 5/301 (1.7)
Chest wall deformity 2/301 (0.7)
Transaortic access
Ministernotomy 288/300 (96.0)
Right anterior thoracotomy 12/300 (4.0)
Alternative access routes
TA feasible 219/301 (72.8)
TF feasible 39/301 (13.0)
Neither TA nor TF feasible 77/301 (25.6)
Values are n/N (%).
TA ¼ transapical; TF ¼ transfemoral; other abbreviations as in Table 1.
TABLE 4 Procedural Outcomes
Procedural success*
Second valve used 5/300 (1.7)
Conversion to surgery 5/300 (1.7)
Periprocedural death 0/300 (0.0)
Valve delivered and catheter retrieved‡ 297/300 (99.0)
Access complications 6/300 (2.0)
Dissection 2/300 (0.7)
Rupture 2/300 (0.7)
Uncontrolled bleeding 3/300 (1.0)
Procedure aborted 0/300 (0.0)
Paravalvular regurgitation
Mild 57/300 (19.0)
Moderate 8/300 (2.7)
Severe 2/300 (0.7)
Central regurgitation
Mild 14/300 (4.7)
Moderate 0/300 (0.0)
Severe 0/300 (0.0)
Intensive care unit stay, days 2.8  5.6
Hospital stay, days 9.9  8.5
Values are n/N (%) or mean  SD. *Procedural success defined as deployment of
one Edwards SAPIEN valve without need for a second valve, no conversion to
conventional surgery, and no intraprocedural death. ‡For 3 patients, we were
unable to obtain information on valve delivery and catheter retrieval, making
98.7% the worst case.
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defined as deployment of the Edwards SAPIEN
valve without need for a second valve or conversion
to conventional surgery, and with no intra-
procedural death (Table 4). A second valve was used
in 1.7% of patients and conversion to surgery was
required in 1.7%. There were no cases of peri-
procedural death. In 99.0% of patients (297 of 300),
the valve was delivered successfully and the cath-
eter was retrieved (no information was available in
3 patients).
The reason for conversion to conventional sur-
gery was valve migration, and left main coronary
artery occlusion intraprocedural with need for
coronary artery bypass grafting in 1 patient each. In
3 patients, conversion to open surgery was neces-
sary due to access complications (rupture and/or
dissection). In total, 2.0% of patients (6 of 300)TABLE 3 Procedural Characteristics
Total procedure time, min 107.0  37.7
Fluoroscopy time, min 12.4  8.5
Quantity of contrast agent used, ml 101.4  48.6
Balloon aortic valvuloplasty 222/300 (74.0)
Balloon post-dilation 70/300 (23.3)
Valve implanted
SAPIEN XT 175/301 (58.1)
SAPIEN 3 126/301 (41.9)
Valve size implanted, mm
23 83/300 (27.7)
26 145/300 (48.3)
29 72/300 (24.0)
Values are mean  SD or n/N (%).experienced access complication. Among the pa-
tients studied, 0.7% (2 of 300) experienced aortic
dissection, 0.7% (2 of 300) aortic rupture, and 1.0%
(3 of 300) major bleeding. Patients with major
bleedings due to access complications had a surgical
intervention without conversion to conventional
surgery. Moderate to severe paravalvular regurgita-
tion was detected in 3.3% of patients with the need
for reoperation in conventional surgery at day 9
after the procedure in 1 patient. Overall, 19.0% of
patients were classified having mild paravalvular
leakage.
The aortic valve peak gradient of 71.4  23.2 mm Hg
(mean) recorded before the TAVR decreased to 17.6 
7.8 mm Hg (mean) after the procedure (Table 5).
Similarly, the aortic valve mean gradient decreased
from 44.3  15.3 mm Hg (mean) before the procedure
to 9.8  4.6 mm Hg (mean) after the procedure
(p < 0.001 for both, including centers as random
factors in the model). Before the intervention, 75.9%
of patients were classified as having New York Heart
Association functional class III or IV disease, which
decreased to 12.1% after the intervention.
FOLLOW-UP OUTCOMES AT 30 DAYS. Overall
30-day mortality was 6.1% (18 of 293), of which
3.1% (9 of 293) was procedure-related mortality and
4.4% (13 of 293) cardiovascular mortality. Other
TABLE 5 Change in Disease-Related Variables
Pre-Procedure Post-Procedure
Aortic valve peak gradient,
mm Hg
71.4  23.2 17.6  7.8
Aortic valve mean gradient,
mm Hg
44.3  15.3 9.8  4.6
Pre-Procedure 30 Days
NYHA functional class I/II, % 72/299 (24.1) 248/282 (87.9)
NYHA functional class III/IV, % 227/299 (75.9) 34/282 (12.1)
Values are mean  SD or n/N (%).
NYHA ¼ New York Heart Association (33); other abbreviation as in Table 1.
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1819complications included myocardial infarction (1.0%),
stroke (1.0%), transient ischemic attack (0.3%),
major vascular complications (3.4%), life-threatening
bleeding (3.4%), and acute kidney injury (9.5%). A
total of 8.8% of patients required permanent pace-
maker implantation during the follow-up period.
Rehospitalization for valve-related symptoms or
deterioration occurred in 3.4% of patients (Table 6).
No influence of age, left ventricular ejection frac-
tion, presence of syncope or dizziness, prior pace-
maker implantation, hypertension, peripheral artery
disease, pulmonary hypertension, TF feasibility,
or country on overall 30-day, procedure-related, or
cardiovascular mortality was found in a logistic
regression.DISCUSSION
The results of ROUTE, with 301 patients undergoing
TAo-TAVR enrolled, demonstrate that the use of TAoTABLE 6 The 30-Day Outcomes According to VARC-2
Criteria (17)
Overall 30-day mortality 18/293 (6.1)
TAVI-related mortality 9/293 (3.1)
Complication rates
Cardiovascular mortality 13/293 (4.4)
MI 3/293 (1.0)
Stroke/TIA 4/293 (1.4)
Permanent pacemaker implantation 26/294 (8.8)
Major vascular complication 10/293 (3.4)
Life threatening bleeding 10/293 (3.4)
Acute kidney injury (stage 2 or 3)* 27/285 (9.5)
Hospitalization for valve-related symptoms
or deterioration
10/293 (3.4)
Values are n/N (%). *Acute kidney injury post-procedural according to the Acute
Kidney Injury Network criteria (17,36).
TIA ¼ transient ischemic attack; VARC ¼ Valve Academic Research Consortium;
other abbreviation as in Table 1.for the implantation of the SAPIEN XT and SAPIEN 3
transcatheter heart valve is a viable alternative
approach.
PROCEDURAL CHARACTERISTICS. The patients
enrolled in ROUTE had a high mean age with multiple
comorbidities, in particular, hypertension, coronary
artery disease, and peripheral artery disease. The
transaortic route was selected for a number of
different reasons. In approximately one-half of cases
this was because it was the standard procedure at that
particular site. Peripheral vascular disease or unsuit-
able vessel were other significant reasons for this
choice. Such a condition makes the TF route, which is
traditionally the preferred option, difficult in many
patients (2,6). On the other hand, respiratory disease
and poor left ventricular function can be contraindi-
cations for the use of TA access (4,7,18,19), conditions
that were found in a small proportion of the patients
included in the registry.
In contrast to other studies, patients who were
suitable for TA- and/or TF-TAVR were not excluded
from this registry. In approximately 25% of patients,
the TAo was deemed to be the only option, whereas
approximately 70% of patients that underwent TAo-
TAVR were also suitable for a TA procedure. A pref-
erence for the TAo route in these patients may have
been due to its less invasive nature, and the
decreased risk of left ventricular wall injury or major
bleeding complications (15,20). Furthermore, sur-
geons are generally more familiar with aortic perfo-
ration in comparison with piercing the apex of the
heart, because aortic perforation is common in open
cardiac procedures (12). This is likely to be a
contributing factor to the reported steep learning
curve associated with TA-TAVR (15,21–23).
PERIPROCEDURAL OUTCOMES. The mean proce-
dure time was similar to or lower than those previ-
ously reported for TAo-TAVR, and similar proportions
of the different sizes of SAPIEN valves were used
(6,24). Procedural success was high, with only small
percentages of patients requiring a second valve
(1.7%) or conversion to open surgery (1.7%). The rates
of these procedural complications were lower than
those reported for TAo-TAVR by Amrane et al. (9) in
44 patients using different valve types (6.8% and
4.6%, respectively), whereas Hayashida et al. (6),
evaluating the efficacy and safety of the TAo-TAVR
approach using either the SAPIEN XT or CoreValve
(Medtronic, Minneapolis, Minnesota), reported con-
version to open surgery in 5.3% of cases. Thourani
et al. (24) reported a rate of open heart surgery
conversion of 2.8%. However, in another study,
no second valves were required and no patients
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The values noted in the present registry are generally
comparable to those previously reported for TF-TAVR
(1.1% to 2.4% for a second valve; 0.8% to 1.7% for
conversion to conventional surgery) (14,25–28), and
for the TA route (0.7% to 2.8% for a second valve;
1.0% to 3.9% for conversion to conventional surgery)
(14,21,24,26–28). No deaths occurred during the
TAo-TAVR procedures included in the present regis-
try, which is in agreement with the low numbers
reported in other studies (6,9,15,24).
There were very few access complications found
when using the TAo-TAVR procedure. This is likely
due to the familiarity of surgeons with aortic in-
terventions. In comparison, ventricular damage and
bleeding have been previously associated with the TA
access route (14,15,20,29). Furthermore, the occur-
rence of arterial injury when using the TF route is
notable (14,30,31).
In general, paravalvular and central regurgitation
were of a mild nature, with only 2 cases of severe
paravalvular leakage documented. In comparison,
moderate or severe paravalvular regurgitation have
been reported in 11% of patients with TAo access
versus 12% by using the TA approach (15).
POST-PROCEDURAL OUTCOMES. A significant decrease
in aortic valve peak gradient was noted post-
procedural, with a similar drop found for the mean
gradient (p < 0.001 for both). Comparable reductions
in pressure gradients have been reported by Thourani
et al. (7,32) for TAo-, TA-, and TF-TAVR using the
SAPIEN valve. The extent of heart failure symptoms,
as categorized according to the New York Heart
Association functional class criteria (33), was also
greatly decreased by the TAVR. The proportion of
patients who were asymptomatic or had mild symp-
toms increased significantly. Accordingly, the per-
centage that had severe limitations in activity
because of their symptoms decreased to below 15%.
At 30 days after the procedure, overall mortality
was assessed to be 6.1%, a value that is similar to that
reported by Hayashida et al. (6) (7.4%) and Amrane
et al. (6.8%) (9), but significantly lower than that
documented by Lardizabal et al. (15) (14.0%) and
Thourani et al. (24) (10.3%). In comparison, studies
regarding TA-TAVR have demonstrated overall
30-day mortalities of 8.8% to 18.2% (14,15,24,26,27),
whereas published values associated with use of TF
access are 8.0% to 11.1% (14,26,31,32). In the present
registry, cardiovascular mortality at 30 days was
found to be 4.4%, with TAVR-related mortality being
3.1%. Lardizabal et al. (15) reported cardiovascular
mortality of 2.0% for TAo-TAVR, whereas the value
documented for TA access was higher at 12.0%.Other complications reported at the 30-day follow-
up were myocardial infarction, stroke or transient
ischemic attack, life-threatening bleeding, and acute
kidney injury; however, the incidences of these
events were low, similar to other studies. Of note,
8.8% of patients required permanent pacemaker
implantation within the first 30 days after the
TAo-TAVR. This value is similar, albeit slightly lower,
compared with that reported by Amrane et al. (9)
(11.4%) and that by Tanawuttiwat et al. (29) (12.5%),
both for TAo. In contrast, the values previously pub-
lished for TA-TAVR are much lower at 5.6% to 7.3%
(14,29,31). It has been shown previously that
implantation of the replacement valve further into
the ventricle is associated with a greater chance of
left bundle branch block (34,35). It is, therefore,
possible that the positioning of the SAPIEN valve
using the TA approach may result in a lower incidence
of left bundle branch block, and accordingly, less
need for permanent pacemaker implantation.
STUDY LIMITATIONS. Although it provides a wealth
of information regarding the efficacy and safety of
TAo-TAVR, the establishment of this registry has
some limitations. First, although the surgeons all
underwent extensive training in the use of TAo-
TAVR with the SAPIEN valves, the analysis may
still be affected by a learning curve. Second, expe-
rience with the procedure is likely to vary with site;
however, the requirement for a minimum of 5 prior
implantations should go some way to reducing any
bias associated with this. Finally, the follow-up
period was confined to 30 days, meaning that
complications in the longer term were not recorded.
A longer follow-up time would provide more
extensive information regarding the safety and ef-
ficacy of the TAo-TAVR procedure. Therefore, we
are currently collecting data for the 1-year follow-up
in these patients.
CONCLUSIONS
ROUTE demonstrates that the use of TAo for the im-
plantation of the SAPIEN XT and SAPIEN 3 trans-
catheter heart valves is a viable alternative to TA
procedures. The high success rate and low occurrence
of complications, both during the procedure and in
the subsequent 30 days, reveal the excellent efficacy
and safety of the technique. Furthermore, overall 30-
day mortality was found to be low.
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PERSPECTIVES
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